CXCR1 and neoplasm: Importantly, we show that the CXCR1/CXCR2 antagonist, SX-682, accomplishes a similar reduction in melanoma tumor burden, establishes an anti-tumor immune microenvironment, and significantly alters the transcriptional profile of melanoma cells when delivered during the transformation process.